{"id":"W2954789649","doi":"10.1200/jco.2019.37.15_suppl.tps7571","title":"POLARIX: A phase 3 study of polatuzumab vedotin (pola) plus R-CHP versus R-CHOP in patients (pts) with untreated DLBCL.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Vincristine; Rituximab; Internal medicine; Diffuse large B-cell lymphoma; Oncology; Phases of clinical research; Cyclophosphamide; Bendamustine; Surgery; Chemotherapy; Lymphoma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001201179,0.001543086,0.001524216,0.0004346357,0.0003759307,0.001271391,0.0008698679,0.001102758,0.007960007],"category_scores_gemma":[0.0007618001,0.0006053878,0.001440236,0.0004154227,0.0009507698,0.0009243037,0.0004204339,0.003960844,0.001404139],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001017006,"about_ca_system_score_gemma":0.001212189,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00122435,"about_ca_topic_score_gemma":0.002246649,"domain_scores_codex":[0.9997857,0.00008868614,0.000007272336,0.00004142852,0.00002389948,0.00005297181],"domain_scores_gemma":[0.9995698,0.00008128808,0.00009540116,0.00003063677,0.00003214434,0.0001905813],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8867247,0.03383888,0.001452888,0.000949694,0.0008476413,0.000137955,0.0001819394,0.00157134,0.01866301,0.0004034435,0.004199628,0.0510289],"study_design_scores_gemma":[0.7698417,0.2217945,0.002863414,0.00005278731,0.0003591492,0.0001890968,0.00006647115,0.000769527,0.001322178,0.0003242193,0.002395811,0.00002122431],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.982671,0.003399073,0.0009640039,0.0009775257,0.0003869396,0.005091739,0.001993753,0.0002795111,0.004236479],"genre_scores_gemma":[0.9785649,0.003600035,0.002448115,0.001946722,0.0003002039,0.004513985,0.003135667,0.0000719384,0.005418438],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007960007,"threshold_uncertainty_score":0.02662885,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08224978446287155,"score_gpt":0.4560757590018102,"score_spread":0.3738259745389387,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}